SpyGlass Pharma, Inc. (SGP) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US85220G1094
SpyGlass Pharma, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -41.45 m USD |
| EBIT | -42.98 m USD |
| Net income | -39.87 m USD |
| Diluted EPS – continuing operations | -17.98 USD |
Full history since 2023, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was incorporated in 2019 and is based in Aliso Viejo, California.
More stocks
- 74Software SA (74SW.PA)
- CITIC Telecom International Holdings Ltd (1883.HK)
- Jiangsu SOPO Chemical Co Ltd (600746.SS)
- Tekla Healthcare Investors (HQH)
- Dongwon Ind (006040.KS)
- Sino Geophysical (300191.SZ)
- Parksystems Corp (140860.KQ)
- BKS Bank AG (BKS.VI)
- Everest Medicines Ltd (1952.HK)
- China Bester Group Telecom Co Ltd (603220.SS)
- Fusheng Precision Co Ltd (6670.TW)
- InventisBio Co. Ltd. A (688382.SS)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.